125 related articles for article (PubMed ID: 12055672)
1. Relationship between p53 pathway and estrogen receptor status in endometrioid-type endometrial cancer.
Maeda K; Tsuda H; Hashiguchi Y; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2002 Apr; 33(4):386-91. PubMed ID: 12055672
[TBL] [Abstract][Full Text] [Related]
2. Expression of tumor suppressor gene product p14ARF in endometrioid adenocarcinoma of the uterine corpus.
Watanabe J; Nishizaki R; Jobo T; Kamata Y; Hata H; Nishimura Y; Fujisawa T; Okayasu I; Kuramoto H
Int J Gynecol Pathol; 2004 Jul; 23(3):234-40. PubMed ID: 15213599
[TBL] [Abstract][Full Text] [Related]
3. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas.
Feng YZ; Shiozawa T; Horiuchi A; Shih HC; Miyamoto T; Kashima H; Suzuki A; Nikaido T; Konishi I
Virchows Arch; 2005 Nov; 447(5):816-22. PubMed ID: 16021509
[TBL] [Abstract][Full Text] [Related]
5. p53 overexpression and mutation in endometrial carcinoma: inverted relation with estrogen and progesterone receptor status.
Niwa K; Murase T; Morishita S; Hashimoto M; Itoh N; Tamaya T
Cancer Detect Prev; 1999; 23(2):147-54. PubMed ID: 10101596
[TBL] [Abstract][Full Text] [Related]
6. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
7. Markers of the p53 pathway further refine molecular profiling in high-risk endometrial cancer: A TransPORTEC initiative.
Edmondson RJ; Crosbie EJ; Nickkho-Amiry M; Kaufmann A; Stelloo E; Nijman HW; Leary A; Auguste A; Mileshkin L; Pollock P; MacKay HJ; Powell ME; Bosse T; Creutzberg CL; Kitchener HC
Gynecol Oncol; 2017 Aug; 146(2):327-333. PubMed ID: 28511869
[TBL] [Abstract][Full Text] [Related]
8. [Relationships between the molecular biomarkers and the clinicopathologic features and prognosis in endometrial carcinoma].
Yao YY; Xu WZ; Wang Y; Shen DH; Wang JL; Wei LH
Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 43(5):743-8. PubMed ID: 22008688
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of estrogen receptor by the methylation of the estrogen receptor gene in endometrial carcinoma.
Shiozawa T; Itoh K; Horiuchi A; Konishi I; Fujii S; Nikaido T
Anticancer Res; 2002; 22(1A):139-43. PubMed ID: 12017277
[TBL] [Abstract][Full Text] [Related]
10. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
11. Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
Lax SF; Pizer ES; Ronnett BM; Kurman RJ
Hum Pathol; 1998 Jun; 29(6):551-8. PubMed ID: 9635673
[TBL] [Abstract][Full Text] [Related]
12. Combined analysis of p53 and RB pathways in epithelial ovarian cancer.
Hashiguchi Y; Tsuda H; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2001 Sep; 32(9):988-96. PubMed ID: 11567230
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and p53 protein expression in the histologic subtypes of endometrial carcinoma.
Ambros RA; Sheehan CE; Kallakury BV; Ross JS; Malfetano J; Paunovich E; Figge J
Mod Pathol; 1996 Dec; 9(12):1165-9. PubMed ID: 8972476
[TBL] [Abstract][Full Text] [Related]
14. Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma.
Li SF; Shiozawa T; Nakayama K; Nikaido T; Fujii S
Cancer; 1996 Jan; 77(2):321-9. PubMed ID: 8625241
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical status of p53, MDM2, bcl2, bax, and ER in invasive ductal breast carcinoma in Tunisian patients.
Baccouche S; Daoud J; Frikha M; Mokdad-Gargouri R; Gargouri A; Jlidi R
Ann N Y Acad Sci; 2003 Dec; 1010():752-63. PubMed ID: 15033823
[TBL] [Abstract][Full Text] [Related]
16. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
17. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications and prognostic value of single and combined biomarkers in endometrial carcinoma.
Li M; Zhao L; Shen D; Li X; Wang J; Wei L
Chin Med J (Engl); 2014; 127(8):1459-63. PubMed ID: 24762589
[TBL] [Abstract][Full Text] [Related]
19. [Characteristic and clinical significance of DNA methyltransferase 3B overexpression in endometrial carcinoma].
Dong Y; Zhou M; Ba XJ; Si JW; Li WT; Wang Y; Li D; Li T
Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Oct; 48(5):788-794. PubMed ID: 27752157
[TBL] [Abstract][Full Text] [Related]
20. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]